Elamipretide (MTP-131, SS-31)

Synonyms: D-Arg-Dmt-Lys-Phe-NH2

Elamipretide (MTP-131, SS-31) is a cytochrome c peroxidase inhibitor. Elamipretide improves mitochondrial dysfunction, synaptic and memory impairment induced by lipopolysaccharide in mice.

Elamipretide (MTP-131, SS-31) Chemical Structure

Elamipretide (MTP-131, SS-31) Chemical Structure

CAS No. 736992-21-5

Purity & Quality Control

Elamipretide (MTP-131, SS-31) Related Products

Biological Activity

Description Elamipretide (MTP-131, SS-31) is a cytochrome c peroxidase inhibitor. Elamipretide improves mitochondrial dysfunction, synaptic and memory impairment induced by lipopolysaccharide in mice.
Targets
cytochrome c peroxidase [1]
In vitro
In vitro

SS-31 binds with high affinity to cardiolipin, an anionic phospholipid expressed on the inner mitochondrial membrane that is required for cristae formation. In addition, the SS-31/cardiolipin complex inhibits cytochrome c peroxidase activity, which catalyzes cardiolipin peroxidation and results in mitochondrial damage during ischemia, by protecting its heme iron.[1]

Cell Research Cell lines feline kidney cells
Concentrations 0.1-10 μM
Incubation Time 1 hour
Method

Intracellular targeting of SS-31 is determined by incubating feline kidney cells, grown in biotin-free media for 24 hours, with biotinylated SS-31 for 1 hour. Cells are then fixed with 4% paraformaldehyde, permeabilized with 0.1% triton, and treated with Streptavidin-AlexaFluor594 for 30 minutes at room temperature. Fluorescence staining is observed by wide-field fluorescent microscope.

In Vivo
In vivo

Pretreatment of rats with SS-31 protects cristae membranes during renal ischemia and prevents mitochondrial swelling. Prompt recovery of ATP on reperfusion leads to rapid repair of ATP-dependent processes, such as restoration of the actin cytoskeleton and cell polarity. Rapid recovery of ATP also inhibits apoptosis, protects tubular barrier function, and mitigates renal dysfunction.[1]

Animal Research Animal Models male Sprague–Dawley rats
Dosages 2.0 mg/kg
Administration SC
NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT05194631 Recruiting
Diaphragm Injury|Mechanical Ventilation Complication
University Hospital Montpellier
February 18 2022 Not Applicable
NCT02914665 Completed
Heart Failure
Stealth BioTherapeutics Inc.
October 20 2016 Phase 2
NCT02848313 Completed
Age-Related Macular Degeneration
Stealth BioTherapeutics Inc.
October 28 2016 Phase 1
NCT02814097 Completed
Chronic Heart Failure
Stealth BioTherapeutics Inc.|Charite University Berlin Germany|SCIRENT Clinical Research and Science d.o.o.
September 2 2016 Phase 2
NCT02436447 Completed
Normal and Impaired Renal Function
Stealth BioTherapeutics Inc.
May 2015 Phase 1

Chemical Information & Solubility

Molecular Weight 639.79 Formula

C32H49N9O5

CAS No. 736992-21-5 SDF --
Smiles CC1=C(CC(NC(=O)C(N)CCCNC(N)=N)C(=O)NC(CCCCN)C(=O)NC(CC2=CC=CC=C2)C(N)=O)C(=CC(=C1)O)C
Storage (From the date of receipt) 3 years -20°C powder

In vitro
Batch:

Water : 100 mg/mL


Molecular Weight Calculator

In vivo
Batch:

Add solvents to the product individually and in order.


In vivo Formulation Calculator

Preparing Stock Solutions

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Elamipretide (MTP-131, SS-31) | Elamipretide (MTP-131, SS-31) supplier | purchase Elamipretide (MTP-131, SS-31) | Elamipretide (MTP-131, SS-31) cost | Elamipretide (MTP-131, SS-31) manufacturer | order Elamipretide (MTP-131, SS-31) | Elamipretide (MTP-131, SS-31) distributor